Skip to content

Markus R Meyer

20 papers in the library · 370 citations · publishing 2009-2026

Papers

Sort Most recent Most cited

Toxicokinetics and analytical toxicology of four N, N-dimethyltryptamine derivatives studied in human in vitro systems and in vivo by means of zebrafish embryos.

Archives of Toxicology September 21, 2026 Gloria Daziani, Lea Wagmann, Matthias D. Kroesen et al.

N,N-Dimethyltryptamine (DMT) is a naturally occurring substituted tryptamine used as a psychedelic drug for ritual purposes by various cultures. Derivatives were already found on the drug of abuse market, such as N1-tert-butoxycarbonyl-N,N-dimethyltryptamine (DMT-Boc). The aim of the current study was to investigate the toxicokinetics of DMT-Boc and three related DMT derivatives, by name...

DOI: 10.1007/s00204-026-04552-3 (opens in new tab) Full text (opens in new tab) Metabolism New psychoactive substances Toxicokinetics Tryptamines

Correction to "Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights".

ACS Chemical Neuroscience March 4, 2026 Nina Kastner, Núria Nadal‐gratacós, Selina Hemmer et al. correction

Correction 1: Table 1.The analyses were conducted using the correct data, and all results, interpretations, and conclusions in the paper remain fully accurate.The issue is limited to the presentation of values in the table.Correction 2: p 4733, second paragraph, 1 st sentence.Thigmotaxis was evaluated to assess potential anxiety-like effects induced by the compounds.When comparing the tested...

In vivo and in vitro toxicokinetics including metabolism, isozyme mapping, and monoamine oxidase inhibition of three (2-aminopropyl)benzo[b]thiophene (APBT) psychedelics.

Toxicology March 1, 2026 Lea Wagmann, Simon D. Brandt, Pierce V. Kavanagh et al.

3-(2-Aminopropyl)benzo[b]thiophene (3-APBT), 5-APBT, and 6-APBT are recently identified psychedelics and entactogens that activate serotonin 2 receptor subtypes and lead to a head-twitch response in mice. The present study characterized their toxicokinetics, metabolism, and monoamine oxidase (MAO) inhibition using liquid chromatography-high-resolution tandem mass spectrometry. Metabolites were...

DOI: 10.1016/j.tox.2026.154402 (opens in new tab) Full text (opens in new tab) Lc-hrms/ms Mao inhibition Metabolism New psychoactive substances +1

Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights

ACS Chemical Neuroscience December 2, 2025 Nina Kastner, Núria Nadal‐gratacós, Selina Hemmer et al.

3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, shows promise in treating depression and post-traumatic stress disorder (PTSD), resulting in breakthrough status. However, concerns regarding MDMA's abuse potential and cytotoxicity have sparked interest in developing safer analogues with similar therapeutic benefits. This study investigated the pharmacological properties of...

DOI: 10.1021/acschemneuro.5c00782 (opens in new tab) MDMA Norepinephrine transporter Monoamine neurotransmitter Dopamine transporter +8

Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing.

British Journal of Clinical Pharmacology June 16, 2025 Wellenberg K Simon, Tanja M Gampfer, Wagmann Lea et al. 1 citation

The aim of this study was to develop a novel workflow to identify human urine biomarkers for drugs of abuse and new psychoactive substances. Metabolites of amphetamine, cocaine, LSD, MDMA, methamphetamine, THC, MDMB-CHMICA, and MDPPP were first identified in a zebrafish embryo (ZE) metabolism study followed by comparison to most abundant human metabolites in literature. Finally, metabolites...

DOI: 10.1002/bcp.70140 (opens in new tab) Full text (opens in new tab) Microdosing Lc‐hrms/ms Drugs of abuse New psychoactive substances +15

Bioisosteric analogs of MDMA: Improving the pharmacological profile?

Journal of Neurochemistry September 1, 2024 Ana Sofia Alberto-Silva, Selina Hemmer, Hailey A. Bock et al. 10 citations

3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy') is re-emerging in clinical settings as a candidate for the treatment of specific neuropsychiatric disorders (e.g. post-traumatic stress disorder) in combination with psychotherapy. MDMA is a psychoactive drug, typically regarded as an empathogen or entactogen, which leads to transporter-mediated monoamine release. Despite its therapeutic...

DOI: 10.1111/jnc.16149 (opens in new tab) Full text (opens in new tab) Psychopharmacology Drug-development Mental-health MDMA-Research +1

Metabolism and cytotoxicity studies of the two hallucinogens 1cP-LSD and 4-AcO-DET in human liver and zebrafish larvae models using LC-HRMS/MS and a high-content screening assay.

Journal of Pharmaceutical and Biomedical Analysis August 1, 2024 Tanja M Gampfer, Victoria Schütz, Philip Schippers et al. 11 citations

The continuous emergence of new psychoactive substances (NPS) attracted a great deal of attention within recent years. Lately, the two hallucinogenic NPS 1cP-LSD and 4-AcO-DET have appeared on the global market. Knowledge about their metabolism to identify potential metabolic targets for analysis and their cytotoxic properties is lacking. The aim of this work was thus to study their in vitro...

DOI: 10.1016/j.jpba.2024.116187 (opens in new tab) Full text (opens in new tab) Cytotoxicity Hepg2 Lc-hrms/ms New psychoactive substances +5

Bioisosteric analogs of MDMA with improved pharmacological profile.

bioRxiv : the preprint server for biology April 11, 2024 Ana Sofia Alberto-Silva, Selina Hemmer, Hailey A. Bock et al. preprint

3,4-Methylenedioxymethamphetamine (MDMA, ' ecstasy' ) is re-emerging in clinical settings as a candidate for the treatment of specific psychiatric disorders (e.g. post-traumatic stress disorder) in combination with psychotherapy. MDMA is a psychoactive drug, typically regarded as an empathogen or entactogen, which leads to transporter-mediated monoamine release. Despite its therapeutic...

DOI: 10.1101/2024.04.08.588083 (opens in new tab) Full text (opens in new tab) Psychedelics Drug development Mental health therapy MDMA Research

Can the Intake of a Synthetic Tryptamine be Detected Only by Blood Plasma Analysis? A Clinical Toxicology Case Involving 4-HO-MET

Journal of Analytical Toxicology June 3, 2021 Lea Wagmann, Sascha K. Manier, Markus R Meyer 11 citations

Tryptamines represent a group of hallucinogenic new psychoactive substances with increasing prevalence. Unfortunately, only limited data concerning their toxicology and bioanalysis are available as tryptamines are not included in routine screening procedures in many laboratories. In order to expand the current knowledge, we report a non-fatal clinical toxicology case involving the synthetic...

DOI: 10.1093/jat/bkab062 (opens in new tab) Tryptamines Forensic toxicology Synthetic cannabinoids Clinical toxicology +3

Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of -lysergic acid diethylamide (LSD)

Neuropharmacology November 19, 2019 Adam L. Halberstadt, Muhammad Chatha, Adam K. Klein et al. 37 citations

The ergoline d-lysergic acid diethylamide (LSD) is one of the most potent psychedelic drugs. 1-Acetyl-LSD (ALD-52), a derivative of LSD containing an acetyl group on the indole nitrogen, also produces psychedelic effects in humans and has about the same potency as LSD. Recently, several other 1-acyl-substitued LSD derivatives, including 1-propanoyl-LSD (1P-LSD) and 1-butanoyl-LSD (1B-LSD), have...

Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases.

Drug Testing and Analysis February 1, 2019 Lea Wagmann, Simon D. Brandt, Alexander Stratford et al. 26 citations

Psychoactive substances of the 2C-series (2Cs) are phenethylamine-derived designer drugs that can induce psychostimulant and hallucinogenic effects. Chemically, the classic 2Cs contain two methoxy groups in positions 2 and 5 of the phenyl ring, whereas substances of the so-called FLY series contain rigidified methoxy groups integrated in a 2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran core. One...

DOI: 10.1002/dta.2494 (opens in new tab) Full text (opens in new tab) Ic50 value Drugs of abuse Monoamine oxidase inhibition Phenethylamines +10

Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach.

Toxicology Letters March 15, 2018 Achim T. Caspar, Markus R Meyer, Hans H Maurer

A huge number of new chemical derivatives of known drugs of abuse, so-called new psychoactive substances (NPS), are sold and consumed without prior preclinical and clinical testing. For assessing the elimination behaviors, determination of the kinetic constants Km and Vmax of the cytochrome P450 (CYP) isoforms involved in the hepatic metabolism of NPS could help to predict their contributions...

DOI: 10.1016/j.toxlet.2017.12.017 (opens in new tab) Full text (opens in new tab) Michaelis-menten kinetic Nbome Relative activity factor Substrate depletion approach

In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks.

Toxicology Letters April 15, 2017 Lea Wagmann, Simon D. Brandt, Pierce V. Kavanagh et al.

Tryptamines have emerged as new psychoactive substances (NPS), which are distributed and consumed recreationally without preclinical studies or safety tests. Within the alpha-methylated tryptamines, some of the psychoactive effects of the prototypical alpha-methyltryptamine (AMT) have been described decades ago and a contributing factor of its acute toxicity appears to involve the inhibition of...

DOI: 10.1016/j.toxlet.2017.03.007 (opens in new tab) Full text (opens in new tab) Drugs of abuse Ic50 value Lc–hr-ms/ms Mao inhibition

Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.

Drug Testing and Analysis 2017 Simon D. Brandt, Pierce V. Kavanagh, Geraldine Dowling et al. 16 citations

Many N,N-dialkylated tryptamines show psychoactive properties in humans and the number of derivatives involved in multidisciplinary areas of research has grown over the last few decades. Whereas some derivatives form the basis of a range of medicinal products, others are predominantly encountered as recreational drugs, and in some cases, the areas of therapeutic and recreational use can...

DOI: 10.1002/dta.1974 (opens in new tab) Full text (opens in new tab) Dalt New psychoactive substances Tryptamines Forensic chemistry +2

Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class.

Toxicology Letters November 17, 2015 Julia Dinger, Campbell Woods, Simon D. Brandt et al.

New psychoactive substances (NPS) are not tested for their cytochrome P450 (CYP) inhibition potential before consumption. Therefore, this potential was explored for tryptamine-derived NPS (TDNPS) including alpha-methyl tryptamines (AMTs), dimethyl tryptamines (DMTs), diallyl tryptamines (DALTs), and diisopropyl tryptamines (DiPTs) using test substrates preferred by the Food and Drug...

Absorption, Distribution, Metabolism and Excretion Pharmacogenomics of Drugs of Abuse

Pharmacogenomics February 1, 2011 Markus R Meyer, Hans H Maurer 107 citations

Pharmacologic and toxic effects of xenobiotics, such as drugs of abuse, depend on the genotype and phenotype of an individual, and conversely on the isoenzymes involved in their metabolism and transport. The current knowledge of such isoenzymes of frequently abused therapeutics such as opioids (oxycodone, hydrocodone, methadone, fentanyl, buprenorphine, tramadol, heroin, morphine and codeine),...

DOI: 10.2217/pgs.10.171 (opens in new tab) Pharmacology Alfentanil Hydrocodone Oxycodone +6

Metabolism of designer drugs of abuse: an updated review.

Current Drug Metabolism June 1, 2010 Markus R Meyer, Hans H Maurer 112 citations

This paper reviews the metabolism of new designer drugs of abuse that have emerged on the black market during the last years and is an update of a review published in 2005. The presented review contains data concerning the so-called 2C compounds (phenethylamine type) such as 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B), 4-iodo-2,5-dimethoxy-beta-phenethylamine (2C-I),...

DOI: 10.2174/138920010791526042 (opens in new tab) Full text (opens in new tab) Drug metabolism Pharmacokinetics Biotransformation Metabolites +19

Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3,4-methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) enantiomers.

Toxicology Letters October 8, 2009 Markus R Meyer, Frank T. Peters, Hans H Maurer

3,4-Methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) are chiral designer drugs distributed on the illicit drug market and they are also N-dealkyl metabolites of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy, Adam), 3,4-methylenedioxyethylamphetamine (MDEA, Eve), and N-methyl-benzodioxolyl-butanamine (MBDB, Eden), respectively. MDA and BDB are mainly metabolized via...

Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers.

Biochemical Pharmacology June 1, 2009 Markus R Meyer, Frank T. Peters, Hans H Maurer

In the present study, cytochrome P450 isozymes (P450) involved in the stereoselective metabolism of the designer drug N-methyl-benzodioxolyl-butanamine (MBDB, Eden) were identified for the first time. Demethylenation and N-demethylation of racemic MBDB as well as its single enantiomers were investigated using cDNA-expressed insect cell microsomes. After incubation of MBDB, the two resulting...

Enantioselectivity in the Methylation of the Catecholic Phase I Metabolites of Methylenedioxy Designer Drugs and Their Capability To Inhibit Catechol-O-methyltransferase-Catalyzed Dopamine 3-Methylation

Chemical Research in Toxicology May 22, 2009 Markus R Meyer, Hans H Maurer 39 citations

The designer drugs R,S-3,4-methylenedioxy-methamphetamine (MDMA, Ecstasy), R,S-3,4-methylenedioxy-ethylamphetamine (MDEA, Eve), and R,S-N-methyl-benzodioxolyl-butanamine (MBDB, Eden) are chiral compounds, and their in vitro and in vivo metabolism is enantioselective with a preference for the S-enantiomer caused in part by P450-mediated demethylenation. As the elimination of the catecholamine...

DOI: 10.1021/tx900134e (opens in new tab) Methylenedioxy Methylation Catechol-o-methyl transferase Microsome +5